The Global Health Body Sounds Concern Over Severe Scarcity of Weight-Loss Medications
Less than 10% of people who could benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it issues its initial advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for more widespread and fairer availability to this class of drugs.
Based on estimates, more than two billion could be obese by 2030 unless action is taken.
"Our new guidance recognises that obesity is a lifelong illness that can be managed with holistic and lifelong treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major hurdles to widespread access to the treatments that can assist patients in reducing substantial body mass, explains the organization.
Skinny Jab Scarcity
Even in the present most favorable outlook, the manufacturing of these medications would only suffice for around 100 million people – less than 10% of eligible patients, according to the health organization.
The guideline calls on governments and firms to increase availability, via measures such as voluntary licensing.
The intellectual property rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.
How Weight-Loss Injections Function
These medications imitate a biological compound to slow digestion, curb appetite and increase feelings of fullness so individuals consume fewer calories.
People usually begin shedding pounds within a few weeks of starting on the weekly injections.
Evidence indicates people may see weight return a year later of stopping the drug, as their typical hunger resume.
To be overweight or obese increases your risk for experiencing medical conditions, like diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity affects people in all nations and was linked to millions of deaths worldwide in 2024, per the WHO.
